The Metformin Use and Gastric Cancer Risk
- Author:
Young-Il KIM
1
Author Information
1. Center for Gastric Cancer, National Cancer Center, Goyang, Korea
- Publication Type:Review Articles
- From:
Journal of Digestive Cancer Report
2020;8(2):97-101
- CountryRepublic of Korea
- Language:English
-
Abstract:
Metformin is a widely used first-line anti-diabetic drug worldwide. Epidemiologic studies using the large population-based cohort database have shown the association between metformin uses and reduced risk of various type cancers including gastric cancer. In the gastric cancer prevention, metformin use was associated with the significant reduction of gastric cancer risk, especially for long-term metformin users. However, there is no well-designed randomized controlled clinical trial investigating the effect of metformin as a chemopreventive drug for gastric cancer. Therefore, further well-designed clinical trials will be needed to implement metformin for chemoprevention of gastric cancer.
